VJOncology is committed to improving our service to you

ASCO 2020 | Advances in mesothelioma treatment

VJOncology is committed to improving our service to you

Dean Fennell

Dean Fennell, PhD, FRCP, of the University Hospitals Of Leicester NHS Trust, Leicester, UK, discusses advances in the treatment of mesothelioma, including the results of the MiST1 study (NCT03654833) which resulted in greater than 50% disease control in BAP1/BRCA1 deficient relapsed malignant mesothelioma treated with rucaparib. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter